Cargando…
Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review
Venous thromboembolism (VTE) is associated with high recurrence, mortality, and cost burden. Direct oral anticoagulants (DOACs) are currently used for VTE treatment, and they offer more benefits over warfarin, despite being more expensive. There is no consensus on the most cost-effective DOAC agent,...
Autores principales: | Al Mukdad, Mohammad, Al-Badriyeh, Daoud, Elewa, Hazem Fathy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714902/ https://www.ncbi.nlm.nih.gov/pubmed/31088296 http://dx.doi.org/10.1177/1076029619849103 |
Ejemplares similares
-
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019) -
Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016) -
Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis
por: Elshafei, Mohamed Nabil, et al.
Publicado: (2020) -
Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018) -
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)